All In MedTech

Device Trial Radar · NCT02373540

Algovita Post-Market Clinical Study: Spinal Cord Stimulation to Treat Chronic Pain

Real-world Evaluation of Outcome Data Under a Prospective, Observational, Post-Market Clinical Study, Using the Algovita SCS System to Treat Patients With Chronic Pain of the Trunk and/or Limbs Per the Applicable Indications for Use

Last checked: Nov 20, 2026Latest source record: Aug 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

91

Actual

Start

Jun 2015

Primary completion

Nov 2019

Study completion Nov 2019

Sponsor

Lead sponsor
NuvectraNot on our public-company list
Sponsor type
Industry
Collaborators
Bright Research Partners
First posted
Feb 27, 2015

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to obtain real-world clinical outcome data for the Algovita Spinal Cord Stimulation system when used, on-label, according to the applicable directions for use.

Conditions

  • Chronic Pain

Interventions

  • Algovita Spinal Cord Stimulation systemDevice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent reduction in targeted pain compared to baselineTime frame: 6 Month Follow-up Visit

Locations

18 sites in 2 countries. Site status is shown where the registry gives one.

  • Summit Healthcare Pain Clinic Associates

    Show Low, Arizona

  • Coastal Pain and Spinal Diagnostics

    Carlsbad, California

  • Samaritan Center for Medical Research

    Los Gatos, California

15 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.